SHANGHAI – It's not often that Chinese biopharmas are able to nab China rights for a promising late-stage oncology candidate in global trials. But that's exactly what Shanghai-based Zai Labs Ltd. did when it obtained exclusive China rights for niraparib from Tesaro Inc.